Publication date: 16/05/2018
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces a contract with Midas Pharma for the development of a sterile injectable product at the Mithra CDMO1 . Midas Pharma, based in Germany, is a full-service provider and a leader in the sourcing and supplying of intermediates, APIs (Active Pharmaceutical Ingredients), FDFs (Finished Dosage Forms) and dossiers for finished products. The company is present in 10 countries and works with generic pharma players, big pharma companies as well as biotech firms.
Financial terms of the contract were not disclosed. Following the umbrella agreement signed with GSP in 2017, this new contract with a highly regarded partner in the field is a further endorsement of the Mithra CDMO.
François Fornieri, CEO of Mithra, commented: “We are very pleased to announce another contract for the injectable section of our Mithra CDMO with a well-known and highly regarded player in the field, and we are looking forward to working with the Midas team on the development as well as the potential manufacturing and supply of the injectable product. The agreements with GSP and Midas underline the confidence of these partners in the Mithra CDMO, and may position us well for future partnering discussions.”
About Midas Pharma
Midas Pharma GmbH, which has its head office in Ingelheim am Rhein (Germany), employs more than 180 staff in 10 countries around the world. Ever since the company was founded in 1988, researchbased pharmaceutical companies and generics companies have relied on Midas’ products and
services. The company is a reputable player in the market thanks to its high-quality staff and its comprehensive service and product portfolio. Midas implements development and sales projects in its two major business areas of active ingredients and finished products. The company has a unique approach to identify market needs and form individual project alliances with partners, each of which bring their own strengths. As a result, Midas covers the entire pharmaceutical, non-clinical value chain – from active ingredient synthesis to marketing authorization for the finished product. Midas does not have its own laboratories or production, and uses its global presence and networks to combine the most suitable partners and best infrastructure for each project.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: